Lilly Asia Ventures’ rapid-fire $450 million fundraise reflects increasing LP interest in the opportunities offered by the Chinese healthcare sector
China-focused Lilly Asia Ventures (LAV) closed its fourth healthcare-focused fund – LAV Biosciences Fund IV – earlier this within two months of launch, hitting the hard cap of $450 million. US institutional...
The government of Shenzhen, China has launched a VC fund with an initial corpus of RMB500 million ($79 million) to invest in blockchain start-ups in the city.
Sequoia Capital China and Serica Partners have co-led an $11 million Series A round for US-based molecular diagnostics start-up NuProbe.
Shenzhen Capital has joined a $30 million Series C round for US-based 3D printing company Formlabs that will support an expansion effort in China and Asia.